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Abstract
Background: A major obstacle to effectively treat and control tuberculosis is the absence of an accurate, rapid, and low-cost
diagnostic tool. A new approach for the screening of patients for tuberculosis is the use of rapid diagnostic classification
algorithms.
Methods: We tested a previously published diagnostic algorithm based on four biomarkers as a screening tool for
tuberculosis in a Central European patient population using an assessor-blinded cross-sectional study design. In addition,
we developed an improved diagnostic classification algorithm based on a study population at a tertiary hospital in Vienna,
Austria, by supervised computational statistics.
Results: The diagnostic accuracy of the previously published diagnostic algorithm for our patient population consisting of
206 patients was 54% (CI: 47%–61%). An improved model was constructed using inflammation parameters and clinical
information. A diagnostic accuracy of 86% (CI: 80%–90%) was demonstrated by 10-fold cross validation. An alternative
model relying solely on clinical parameters exhibited a diagnostic accuracy of 85% (CI: 79%–89%).
Conclusion: Here we show that a rapid diagnostic algorithm based on clinical parameters is only slightly improved by
inclusion of inflammation markers in our cohort. Our results also emphasize the need for validation of new diagnostic
algorithms in different settings and patient populations.
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Introduction
Tuberculosis is causing an estimated 1.7 million deaths per year
and the highest burden of disease is found in regions of high HIV
prevalence. [1] One of the main obstacles to effective treatment
and control of tuberculosis is a lack of accurate, rapid, point-of-
care and low-cost diagnostic tools. [2] Radiology and microscopy
of sputum samples remain the most important diagnostic tools in
low-income regions and culture, PCR, histology, and radiology are
additional valuable diagnostic tools in high-income countries.
Recently, the development of automated molecular tests for the
diagnosis of pulmonary tuberculosis showed promising results,
however this diagnostic approach is less useful for extra-pulmonary
infections. [3] To date no diagnostic method is therefore able to
provide high diagnostic accuracy in a timely manner for
pulmonary and extra-pulmonary tuberculosis. Other diagnostic
tools including the Mendel Mantoux skin test or interferon gamma
release assays cannot reliably discriminate between latent infection
and active disease. [4,5] PCR based diagnostic tools are rapid and
show promising diagnostic accuracy in sputum positive tubercu-
losis, however cost and extrapulmonary infections are limiting its
usefulness.[6–8] Recently developed FACS based diagnostic
methods for extra-pulmonary tuberculosis show promising di-
agnostic results but necessitate advanced technical equipment and
skills, and wait for prospective evaluation in different patient
populations. [9] Similarly, current efforts to identify novel
biomarkers or screening rules for tuberculosis have not yet
resulted in a reliable candidate molecule for further clinical
assessment.[10–14].
Based on proteomic fingerprinting of serum Agranoff and
colleagues proposed a rapid screening test for active tuberculosis
based on the measurement of inflammation parameters including
C-reactive protein, transthyretin, serum amyloid A, and neopterin.
[15] The proposed classification-model was established by
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machine learning methods to obtain the best diagnostic algorithm.
[16,17] In that publication a diagnostic accuracy of up to 84% was
reported in a prospectively obtained data set for the detection of
active cases of primarily pulmonary tuberculosis. Although this test
performance is far from perfect, a reliable algorithm might
considerably help in classifying patients in high or low probability
for tuberculosis. This might help to focus more time consuming
and resource intensive investigations only on persons with high
pre-test probability. To better appreciate the diagnostic potential
of the previously published algorithm external validity needs to be
assessed in different patient populations.[18–20].
The aim of this study was to assess the external validity of the
initially reported diagnostic algorithm for the diagnosis of active
pulmonary and extra-pulmonary tuberculosis in a Central Euro-
pean cohort. In addition we aimed to establish improved screening
algorithms by machine learning methodology. For this purpose we
aimed to construct two models – one including all useful
laboratory and clinical parameters, and another model relying
entirely on clinical information. The development of a diagnostic
algorithm based on clinical information only was judged to being
particularly useful for low-income regions.
Materials and Methods
Study Design and Outcome Parameters
This study was designed as a cross-sectional study. The study
population consisted of 439 patients with clinical suspicion for
active tuberculosis. All patients attending as out- or in-patients the
Department of Infectious Disease at the Vienna General Hospital,
Medical University of Vienna, between October 2001 and June
2008 were considered eligible, if the treating physician had
requested laboratory testing of any biologic samples for mycobac-
terial culture.
Cases were classified as suffering from active tuberculosis by
either a positive culture result for M. tuberculosis or a diagnosis
based on either histology or radiology results suggestive for active
tuberculosis and clinical cure following administration of specific
anti-tuberculosis treatment. Non-tuberculosis patients were de-
fined as subjects for whom biological samples had been sent for
mycobacterial culture, but for whom an alternative diagnosis was
established. Patients with HIV infection and paediatric patients
were excluded from further analysis.
Patients being evaluated for tuberculosis routinely underwent
assessment of serum inflammation markers at our institution.
Those individuals for whom no results for acute phase parameters
were available were excluded from further analysis. The in-
flammation parameters C-reactive protein, serum amyloid A,
fibronectin, haptoglobin, and interleukin 6 were assessed routinely
by nephelometry (Siemens DADE BN II). Similarly haematology,
clinical biochemistry and blood sedimentation rates were per-
formed routinely. Neopterin and transthyretin were analysed for
the purpose of this study by ELISA (neopterin, Enzyme Linked
Immunoassay, IBL Hamburg, Germany) and nephelometry
(transthyretin, Siemens DADE Behring BN II) using frozen serum
samples. Clinical information, microbiologic culture results, and
results of histopathology and radiology were obtained from
electronic patient records.
Ethics Statement and Statistical Analysis
All participants provided written consent for the use and
analysis of data and archived specimens. The study protocol was
approved by the Ethics Committee of the Medical University of
Vienna (EK: 724/2007). All data were pseudonymized and were
entered into an electronic database and statistical analysis was
performed using a commercially available software package (SPSS
Statistics 16.0, SPSS Inc.). For comparison between groups
Pearson’s x2-test or a Mann-Whitney-U-test was applied as
appropriate. Statistical significance was defined at a level of
a= 0.05 and the Bonferroni-Holm approach was used for
correction for multiple testing. For the purpose of validating
a previously published diagnostic algorithm, outcome information
was masked and data were sent for outcome prediction to the trial
statistician of the previous study. [15] Classification of patients was
performed by the blinded statistician and the outcomes were
returned for the evaluation of the diagnostic accuracy for this data
set. Further analysis was performed using various supervised
machine learning techniques. We applied different such methods
for classifying the feature based data into classes (TB, not TB), as
desired.
Briefly describing the used methods, (I) a support vector
machine (SVM) generates a discriminant function from training
samples, based on so-called support vectors, maximizing the
margin between classes. [21] Furthermore, (II) the ADTree +
AdaBoost algorithm iteratively improves ‘‘weak’’ decision trees to
a ‘‘strong’’ model, i.e., focusing on those instances that were
misclassified in the previous iteration. [22] Furthermore, different
prediction models were established using the (III) naı¨veBayes
algorithm, calculating prior-, conditional- and posterior-probabil-
ities, (IV) the logistic regression classifier, characterized by
membership function for each class, and (V) the multi-layer
perceptron (an artificial neural network), combining various linear
models for non-linear classification.[21,23–25] In this context
attribute evaluators serve the purpose to skip irrelevant parameters
of the data set prior to classification. Further optimization was
performed by the discretization filter that converts continuous to
nominal values and the principal components analysis (PCA),
which transforms conceivably correlated parameters to an un-
correlated set of variables (i.e., transforms the variables to
a different space, using the principal components as ba-
sis).[23,26–28].
The Java based software suite WEKA (Waikato Environment
for Knowledge Analysis, version 3.6.2, URL: http://www.cs.
waikato.ac.nz/ml/weka/,licensed under GNU General Public
License) was applied for the construction of improved diagnostic
algorithms. [29] Missing values were not imputed in our data set.
Optimization results of the models were assessed in internal
validation. All training sets were trained with all major supervised
classifying algorithms, maximizing the accuracy. When equal
accuracy was rated, better Receiver Operating Characteristic
(ROC) curve was used as selection criteria. [30] The outcome of
the machine learning process was evaluated in a stratified 10-fold
cross validation. [31,32].
Results
Following inclusion and exclusion criteria on all subjects being
consecutively screened for tuberculosis a study population of 206
patients was constituted. 233 patients were excluded from further
analysis, due to the unavailability of stored blood specimens (172
patients), missing data or loss of follow up (35 patients), diagnostic
uncertainty or patients already receiving tuberculostatic therapy at
the time of first physician’s contact (18 patients), infection with
Mycobacteria other than tuberculosis (MOTT, 3 patients), HIV
infection (4 patients) and age (1 patient).
Among those individuals 36 had a definitive diagnosis of active
tuberculosis and 170 patients were suffering from other conditions
(see: table 1). Distribution of diagnostic test for establishing
diagnosis of active tuberculosis is presented in table 2. Clinical and
Diagnostic Algorithm for Tuberculosis
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laboratory characteristics of the study population are depicted in
table 3. Median age, body mass index, C-reactive protein, serum
amyloid A and were all significantly lower in tuberculosis than in
non-tuberculosis patients in univariate analysis after adjustment
for multiple testing using the Bonferroni-Holm procedure.
Evaluation of Diagnostic Algorithm
The data set was masked for outcomes and sent to the authors
of the previously published study for analysis. Predicted outcomes
were used for computation of diagnostic accuracy of the diagnostic
algorithm in our patient population. One patient had to be
excluded in this evaluation due to missing transthyretin values.
Predicted outcomes are depicted in table 4.
In summary, the Gaussian kernel based support vector machine
model (SVM 1) yielded a moderate diagnostic accuracy of 54%
(47%–61%) when applied to our patient population showing
sensitivity and specificity of 19% (8%–36%) and 62% (52%–71%),
respectively. The second evaluated model, the meta-classifier
model (AD 2) reached a diagnostic test accuracy of 42% (35%–
49%) sensitivity: 58% (40%–75%), specificity: 38% (31%–46%).
Development of Extended Diagnostic Algorithms
We aimed to develop two new diagnostic models by a machine
learning approach – one making use of all available parameters
(‘‘Optimal Performance Algorithm’’) and an alternative restricted
to the use of clinical parameters (‘‘Clinical Data Algorithm’’).
Firstly, most potent feature sets were identified to maximize the
performance of the classification model. The feature selection
process was started with single attribute evaluators, combined with
a ranker search. All standard single attribute evaluators led to
similar results, identifying the following six parameters: age, body
mass index, C-reactive protein, serum amyloid A, weight loss, and
night sweat. In an additional step, attribute subset evaluators were
used on the original feature set and age, body mass index, C-
reactive protein, and serum amyloid A were identified as
evaluators. These results were consistent with the univariate
analysis of variables. Two training sets were created with the aim
to obtain two distinct diagnostic algorithms. Firstly we aimed to
maximize test performance by including all useful parameters.
Secondly we intended to construct a model that entirely relies on
clinical information and may therefore prove particularly useful in
low-income regions lacking the infrastructure to perform labora-
tory analysis of inflammation markers.
We tested the parameter sets with principal component analysis,
the entropy based discretization method of Fayyad and Irani and
a combination of both methods. [27,28] The approach resulting in
the best outcome in a stratified 10-fold cross validation was chosen.
These included the following attributes for the ‘‘optimal perfor-
mance set’’: age, body mass index, C-reactive protein, night sweat.
The discretization method of Fayyad and Irani, which yielded into
improved models in this training set, was not able to establish
discrete counterparts of serum amyloid A. For the clinical data
model the parameters age, body mass index, and night sweats were
identified.
All major supervised machine learning techniques were applied
and evaluated by an internal 10-fold cross validation. According to
these results, a logistic regression based classifier, the Naı¨ve Bayes
algorithm and a multilayer preceptor were identified as superior in
our data set. Logistic regression based classification was performed
with the ridge estimator of leChessie and van Houwelingen to
establish an improved diagnostic model. [33] Naı¨ve Bayes was
used in standard settings. The multilayer preceptor was performed
in standard settings using 4 hidden layers. [29].
The ‘‘Optimal Performance Algorithm’’ evaluated those
parameters with best data pre-processing performance. The
logistic regression based classifier was enhanced by the use of
the discretization filter, and the Naı¨ve Bayes was improved by the
application of principal component analysis and the discretization
filter.
Employing these settings a diagnostic accuracy of 86% (80%–
90%) was achieved for our patient population with an area under
the curve (AUC) of the receiver operating characteristic (ROC) of
0.78. In this analysis the sensitivity was 42% (26%–59%) and the
specificity was 95% (91%–98%). The true positive rate for
tuberculosis cases in our study population was between 42% and
61% (see: table 4).
For the evaluation of the ‘‘Clinical Data Algorithm’’ the
multilayer preceptor employing in standard settings showed the
best accuracy. A diagnostic accuracy of 85% (79%–89%) could be
achieved. Sensitivity [31% (16%–48%), specificity: 96%, (92%–
98%)] and the AUC of the ROC curve (0.7) was lower than the
Table 1. Baseline characteristics of study population.
Type of disease N Group-Percentage
Auto-immune disease 11 6%
FUO 28 17%
Airway infection 64 38%
Abdominal infection 7 4%
Abscess 5 3%
Bone and joint-infection 3 2%
Soft tissue or foreign body-
infection
4 2%
Endocarditis, pericarditis 9 5%
Neoplasm 35 21%
Other 4 2%
Total 170 100%
Type of tuberculosis
Pulmonary TB 18 50%
Extra-pulmonary TB 15 42%
Miliary TB 3 8%
Total 36 100%
FUO= fever of unknown origin, TB = tuberculosis.
doi:10.1371/journal.pone.0049658.t001
Table 2. Type of confirmation of active tuberculosis.
Detection method1 N Group-Percentage
Clinically proven2 5 14%
Microscopy 2 6%
Histology 9 25%
PCR proven 5 14%
Culture proven 15 42%
Total 36 100%
1classification into one category based on hierarchical evidence: culture, PCR,
histology, microscopy, clinical prove;
2with adequate response to therapy, PCR= Polymerase Chain Reaction, IGRA=
Interferon Gamma Release Assay.
doi:10.1371/journal.pone.0049658.t002
Diagnostic Algorithm for Tuberculosis
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previously established model. The logistic model combined with
discretization and principal components analysis led to a similar
result but to a lower ROC curve (see: table 4).
Discussion
Rapid and reliable diagnostic tests for tuberculosis are urgently
needed and the previously published diagnostic algorithms showed
highly encouraging accuracy. Provided that this good diagnostic
precision is reproducible for diverse patient populations and
settings, such a rapid assessment tool, which could be part of
a point-of-care test for active tuberculosis, would constitute a major
improvement in the diagnosis, management, and control of
tuberculosis. [34].
In this study the previously published diagnostic classification
model was evaluated in a Central European patient population.
The diagnostic accuracy was disappointingly low at 54% and
42%. This poor diagnostic performance may be explained by
various factors. Whereas the analysis of data was identical in both
studies – and classification of cases was performed by the same
person as in the initial study – the patient population under
investigation differed considerably between the two studies.
Whereas Agranoff and colleagues worked with a study popu-
lation predominantly suffering from pulmonary tuberculosis, our
study population included a significant proportion of patients with
extra-pulmonary tuberculosis. However, in our data set the
diagnostic accuracy of the Agranoff model was not significantly
improved when restricting the analysis to only those individuals
suffering from pulmonary tuberculosis [n = 19; accuracy: 58%
(SVM) and 41% (AdaBoost) see: table 4].
Contrary to the previous study, no HIV seropositive patients
were included in our study. Other potential differences may
include variations in treatment seeking behaviour, diagnostic
approaches of caring physicians, differences in ethnicity of
patients, and a discrepancy in pre-test probability based on an
unequal numeric distribution of cases and controls.
Whereas an equal number of cases and controls was selected in
Agranoffs study following a case-control study design, we used
a cross-sectional study design applying predefined inclusion and
exclusion criteria in order to avoid an artificially high proportion
of tuberculosis patients in our data set. Therefore all consecutive
patient with clinical suspicion for tuberculosis were included
leading to a 1:4 distribution of tuberculosis and non-tuberculosis
patients, respectively. Differences in the pre-test probability
invariably affect the performance of diagnostic models and may
be an explanation of impaired generalizability of both the
previously published and the newly established model.
In addition, the ethnic origin of patients was unevenly
distributed in Agranoff’s training set. Whereas 79% of tuberculosis
patients originated from sub-Saharan Africa in the training set, the
proportion Africans was only 34% in the control group.
Furthermore the control group in that study was heterogeneous
consisting of both patients suffering from inflammatory conditions
Table 3. Clinical and laboratory characteristics of tuberculosis and non-tuberculosis patients.
Non-tuberculosis group
(N=170)
Tuberculosis
group (N=36)
N % N % p-value1
Male 103 61% 16 44% 0.075
Weight loss 69 41% 12 32% 0.596
Night sweat 64 39% 11 30% 0.671
parameter cut off** median IQR median IQR p-value2
Age 54 27 36 26 0.000*
C-reactive protein mg/l ,0.02 6 12 1 4 0.000*
Serum amyloid A mg/dl ,3.9 164 372 38.5 139 0.001*
Body mass index kg/m2 n.l. 23.2 5.9 19.1 5.2 0.005*
Mean corpuscular volume fl n.l. 86.8 8 83.4 8 0.017
White blood count G/l n.l. 7.9 5.4 6.1 2.8 0.017
Interleukin-6 pg/dl ,7 7 24 4 7 0.027
Haptoglobin mg/dl ,12 242 161 173 211 0.044
Temperature uC n.l. 38 1.7 37.4 2 0.150
BSR3 2 h mm n.l. 80 40 72 38 0.151
Neopterin nmol/l ,1.35 11.7 19.6 8.8 13.7 0.183
BSR3 1 h mm n.l. 68 44 60 39 0.186
Transthyretin mg/dl ,5 16.1 12 17.3 13 0.243
Fibronectin mg/dl ,15 32 15 29 13 0.285
Hemoglobin g/dl n.l. 12.2 3.2 12.3 2.7 0.556
1Pearsons x2-test, nominal scale: yes or no.
2U-test, continuous scale.
3BSR: blood sedimentation rate.
*Statistically significant after adjusting for multiple testing by Bonferroni-Holm correction.
**typical analytical sensitivity-lower boundary (test kit lot depending), n.l. = no limit.
doi:10.1371/journal.pone.0049658.t003
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and healthy volunteers. Whereas limitations of our study are the
retrospective identification of this patient cohort, a limited sample
size, and exclusion of potential participants due to missing data for
a proportion of identified subjects, a great emphasis was laid on
the constitution of a homogenous comparator that was entirely
chosen based on the exposure (suspicion for tuberculosis) and not
for the outcome under investigation (diagnosis of tuberculosis). All
these factors may explain the lower than expected diagnostic
accuracy of the initially published model and stress the need for
further improvement and prospective evaluation of this diagnostic
algorithm in various clinical settings.
Following our goal to develop an improved diagnostic
algorithm, we used machine learning methodology to obtain an
improved diagnostic algorithm. The ‘‘Optimal Performance
Algorithm’’, including age, body mass index, night sweat, C-
reactive protein led to a diagnostic accuracy of 86% (80%–90%)
with an AUC of the ROC-curve of 0.78 in an internal 10-fold
cross validation. Similarly the ‘‘Clinical Data Algorithm’’,
consisting of age, body mass index and night sweat, had
a diagnostic accuracy of 85% (79%–89%) and an AUC-ROC of
0.70. Considering the ease of obtaining the respective clinical
parameters and the variability in the model estimation the Clinical
Data Algorithm seems particularly useful. This finding may also be
interpreted in that way that the inclusion of inflammation
parameters does not significantly improve diagnostic models in
tuberculosis. However further prospective evaluation in these
diverse clinical settings and comparative evaluation to the
diagnostic accuracy by a skilled physician is warranted in future
prospective studies.
Considering the presented results, no final judgment may
therefore be given whether machine learning based diagnostic
algorithms are an appropriate screening method for tuberculosis
or not. Arguably clinical parameters of patients suffering from
tuberculosis may vary considerably and other parameters than
inflammation parameters may prove more suitable as markers for
the screening of patients. These markers may include serum
concentrations of calcium [35–37], iron [38], vitamin D [39–41]
or orosomucoid [42,43] and it may prove rewarding to evaluate
those alone or in combination in future diagnostic algorithms.
Table 4. Diagnostic performance of tested diagnostic algorithms.
Model Prediction Accuracy Sensitivity Specificity AUC-ROC*
Pos Neg
Support vector machine (Agranoff model, SVM 1)1
True TB 7 29 54.2% (47.1%–61.1%) 19.4% (8.2%–36.0%) 61.5% (51.5%–71.0%) –
True NonTB 65 104
ADTree + AdaBoost (Agranoff model, AD 2)2
True TB 21 15 42.0% (35.1%–49.0%) 58.3% (40.1%–74.5%) 38.5% (31.1%–46.2%) –
True NonTB 104 65
Support vector machine (Agranoff model, SVM 1, without extrapulmonary TB)3
True TB 4 14 57.8% (50.3%–65.0%) 22.2% (6.4%–47.6%) 61.5% (53.8%–68.9%) –
True NonTB 65 104
ADTree + AdaBoost (Agranoff model, AD 2, without extrapulmonary TB)4
True TB 11 7 40.6% (33.5%–48.1%) 61.1% (35.8%–82.7%) 38.5% (31.1%–46.2%) –
True NonTB 104 65
Logistic regression 1 (Optimal Performance Algorithm)5
True TB 15 21 85.9% (80.4%–90.3%) 41.7% (25.5%–59.2%) 95.3% (90.9%–98.0%) 0.78
True NonTB 8 162
Naive Bayes 1 (Optimal Performance Algorithm)6
True TB 22 14 81.1% (75.0%–86.2%) 61.1% (43.5%–76.9%) 85.3% (79.1%–90.3%) 0.79
True NonTB 25 145
Logistic regression (Clinical Data Algorithm)7
True TB 13 23 84.5% (78.8%–89.1%) 36.1% (20.1%–53.8%) 94.7% (90.2%–97.6%) 0.66
True NonTB 9 161
Multilayer Perceptor 2 (Clinical Data Algorithm)8
True TB 11 25 84.5%(78.8%–89.1%) 30.6% (16.4%–48.1%) 95.9% (91.7%–98.3%) 0.7
True NonTB 7 163
AUC-ROC=Area under the Receiver Operation Characteristic curve; pos = positive, neg= negative.
95% confidence intervals are computed according binominal formula of Clopper and Pearson [44].
1,2N = 205;
3,4N = 187, 18 patients excluded due to extrapulmonary TB;
5N= 205, with discretization, including: age, body mass index, C-reactive protein, night sweat;
6N = 205,with discretization, principal components analysis; including: age, body mass index, C-reactive protein, night sweat;
7N = 205, with discretization, principal components analysis; including: age, body mass index, night sweat;
8N = 205, with normalization, 4 hidden layer; including: age, body mass index, night sweat;
doi:10.1371/journal.pone.0049658.t004
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In summary this study demonstrates low external validity of the
previously published machine learning based diagnostic algorithm
when evaluated for our patient population. Although diagnostic
algorithms with improved diagnostic precision were established
based on data of a Central European patient population, further
independent prospective evaluation of these models is needed to
better appreciate the potential of machine learning based di-
agnostic algorithms for the rapid screening of patients for active
tuberculosis.
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